What is your approach to pre-menopausal or male breast cancer patients on adjuvant tamoxifen who develop a DVT, in the absence of other risk factors for thromboembolic disease?  

The treatment of male breast cancer is similar to premenopausal female breast cancer with respect to endocrine therapy. The 2 acceptable options for treatment are, therefore, either Tamoxifen or Aromatase Inhibitors + GNRH agonists. In patients with DVT, I would favor switching from Tamoxifen to AI+...